FindTrial
Sign In

hepatic artery infusion chemotherapy

PROCEDURE6 trials

Sponsors

The Central Hospital of Lishui City, RenJi Hospital, First Hospital of China Medical University, Shanghai Zhongshan Hospital

Conditions

BCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaHCC - Hepatocellular CarcinomaHepatic Arterial Infusion ChemotherapyHepatocellular CarcinomaHepatocellular Carcinoma (HCC)Immune Checkpoint InhibitorsLenvatinib

Unknown Phase

HAIC Combined With Second-line Target Immunity for HCC With TACE Standard Treatment Low Response or Failure
NCT05233358
The Central Hospital of Lishui CityHepatocellular Carcinoma
Start: 2022-02-01End: 2025-02-01Target: 176Updated: 2022-02-10
Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
RecruitingNCT06519578
RenJi HospitalHepatocellular Carcinoma
Start: 2024-08-01End: 2027-07-31Target: 1115Updated: 2024-08-07
HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
RecruitingNCT06632093
First Hospital of China Medical UniversityBCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy +3
Start: 2024-09-16End: 2025-12-30Target: 84Updated: 2024-10-08
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC
Active, not recruitingNCT06632106
First Hospital of China Medical UniversityHepatic Arterial Infusion Chemotherapy, Hepatocellular Carcinoma (HCC), Immune Checkpoint Inhibitors +1
Start: 2024-08-16End: 2025-05-30Updated: 2024-10-08
HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)
CompletedNCT06631326
First Hospital of China Medical UniversityBCLC Stage C Hepatocellular Carcinoma, HCC - Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy +2
Start: 2021-01-01End: 2025-10-22Updated: 2026-01-27
The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
Not yet recruitingNCT07724951
Shanghai Zhongshan HospitalHepatocellular Carcinoma (HCC)
Start: 2026-07-31End: 2028-07-31Target: 400Updated: 2026-07-27

Related Papers

Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus: A target trial emulation study (CHANCE 2416).
Journal of Clinical Oncology2026-05-27
Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): study protocol of a multicentre, retrospective, target trial emulation design
BMJ Open2025-09-01
Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus.
Journal of Clinical Oncology2025-05-28